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INTRODUCTION
Mucosal malignant melanoma (MMM) of the sinonasal tract ac-
counts for 1% of all mucosal melanomas and 3-4% of malignant
neoplasms of the sinonasal tract (1). In MMM, most lesions are
limited to the nasal cavity and paranasal sinuses without nodal
or distant metastasis. However, this disease has a unique, multi-
focal characteristic which makes it difficult to obtain a clear resec-
tion margin (2-4). For this reason, MMM of the sinonasal tract has
a high recurrence rate and a poor prognosis. Our previous report
also demonstrated a poor 5-yr overall survival rate of approxi-
mately 27.2% (5).
Angiolymphatic invasion, tumor thickness, and a wide margin
of surgical resection are widely accepted predictors of survival
rate (6, 7). The Ki67 antigen is an indicator of proliferative activ-
ity, and numerous studies have shown that Ki67 immunohisto-
chemical staining is an effective method to predict prognosis in
various tumors, including cutaneous melanoma (8, 9). However,
the association between immunohistochemical staining for Ki67
and prognosis has not yet been studied in MMM of the sinonasal
tract. 
Thus, our primary objectives were to analyze the clinical fea-
tures of sinonasal MMM and to determine whether Ki67 expres-
sion is correlated with prognosis.
MATERIALS AND METHODS
Subjects
From March 1995 through January 2007, the medical records of
27 patients who were diagnosed and treated for malignant mel-
anoma of the sinonasal tract at our hospital were reviewed ret-
rospectively. The patients were diagnosed as having malignant
Objectives. Sinonasal mucosal melanoma is a rare and aggressive disease. The aim of this study was to analyze the clini-
cal features of patients with sinonasal mucosal melanoma and to determine the role of Ki67 antigen as a predictor of
prognosis in sinonasal mucosal melanoma.
Methods. This was a retrospective case- series study at a single institution, an academic tertiary referral center. From 1995
to 2007, 27 patients with sinonasal mucosal melanoma were reviewed retrospectively, and the expression of Ki67
antigen was assessed by immunohistochemistry.
Results. The overall 5-yr survival rate was 33.9%. No significant differences were observed in 5-yr survival according to
age, sex, stage, or the presence of melanin. The rates of local failure, regional failure, and distant failure were 37.0%,
14.8%, and 11.1%, respectively. Patients with spindle or mixed cell types had better prognoses than those with other
cell types. At a cut-off value of 35%, patients with lower Ki67 scores showed better survival than those with high-
er Ki67 scores.
Conclusion. The presence of spindle or mixed cell types may indicate a better prognosis than other cell types. Ki67 immunos-
taining may be a useful predictor of prognosis in patients with mucosal malignant melanoma of the sinonasal tract.
Key Words. Ki67 antigen, Melanoma, Nasal cavity, Paranasal sinuses
Ki67 Antigen as a Predictive Factor for Prognosis of
Sinonasal Mucosal Melanoma
Dong-Kyu Kim, MD
1 Dae Woo Kim, MD
1 Si Whan Kim, MD
1 Dong-Young Kim, MD
1 Chul Hee Lee, MD
1
Chae-Seo Rhee, MD
1,2
1Department of Otorhinolaryngology, College of Medical and Research Center for Sensory Organs, Medical Research Center, Seoul National
University; 
2Allergy & Clinical Immunology, Medical Research Center, Seoul National University, Seoul, Korea
�Received September 3, 2008 
Accepted after revision September 18, 2008
�Corresponding author : Chae-Seo Rhee, MD
Department of Otorhinolaryngology, Seoul National University Hospital,
101 Daehangno, Jongno-gu, Seoul 110-744, Korea
Tel : +82-2-2072-3991,  Fax : +82-2-745-2387
E-mail : csrhee@snu.ac.kr
DOI 10.3342/ceo.2008.1.4.206 Clinical and Experimental Otorhinolaryngology    Vol. 1, No. 4: 206-210, December 2008
Original ArticleKim D-K et al.: Ki67 Antigen in Sinonasal Mucosal Melanoma 207
melanoma based on the presence of melanin pigment in the
tumor cells and immunohistochemical staining for HMB-45 and
S-100. The population in the present study consisted of 15
males and 12 females with a median age of 62 yr (range, 41 to
87 yr). The average follow-up period was 28.2 months (range, 3
to 104 months). We used Stern’s staging system to classify
lesions as follows; Stage I confined to the primary site (local dis-
ease), Stage II with regional lymph node metastasis, Stage III
distant metastasis (10). 
All patients underwent surgery. In 18 patients an en bloc exci-
sion was performed with a sufficient margin of resection, regard-
less of stage. Three patients received additional immunotherapy
with interferon (IFN)-αafter surgery. Surgery and postoperative
radiation therapy was performed in four patients. Two patients
was underwent surgery followed by both immunotherapy and
radiation therapy (Table 1). We evaluated the survival rates of
27 patients with MMM according to age, sex, and stage. The pres-
ence of melanin and histological cell type were evaluated in 21
patients. Regarding these factors, we could not evaluate 6 patients
because preoperative slides were not available.
Immunohistochemical staining
The Ki67 immunohistochemical staining was performed in avail-
able 13 tissues which were preserved in paraffin block and the
others 14 were preserved on slide only. Paraffin-embedded sec-
tions were cut to a thickness of 4 μ m, deparaffinized in xylene
for 30 min, and then rehydrated in 100%, 95%, and 70% ethanol
for 3 min each. The sections were then washed in distilled water
for 3 min. For antigen retrieval, the sections were placed in 0.1%
citrate buffer (pH 6.0) and heated in a microwave oven for 30 min.
Endogenous peroxidase activity was blocked with 3% H2O2 for
5 min, and the slides were washed in phosphate-buffered saline
(PBS, 0.1 mol/L, pH 7.4). The tissues were incubated in 10% fetal
bovine serum (FBS) and TBST (1% TBS and Tween 20) at room
temperature for 20 min to prevent non-specific protein binding.
The tissues were then incubated with the primary antibody (anti-
Ki67, clone MIB-1; DAKO, Glostrup, Denmark) at a dilution of
1:40 for 12 hr, followed by three washes in PBS. The secondary
antibody (biotinylated IgG, mouse/rabbit; DAKO), was applied
for 25 min, followed by one wash in PBS. Finally, the sections
were incubated with HRP-conjugated streptavidin (DAKO) for
20 min, followed by two washes in PBS. The sections were coun-
terstained with Mayer’s hematoxylin. A pathologist with no back-
ground knowledge of the present study performed the immuno-
histochemical analysis. Melanin staining was detected in the cyto-
plasm, whereas Ki67 was detected in the nuclei of tumor cells.
In areas with definite nuclear staining, the number of Ki67-pos-
itive tumor cells was counted per 300 tumor cells and the per-
centage was calculated (Fig. 1).
Stage I Stage II Stage III
Table 1. Initial treatment modalities
IT: Immunotherapy; RT: radiotherapy.
Surgery only 15 2 1
Surgery+IT 3 0 0
Surgery+RT 3 1 0
Surgery+RT+IT 2 0 0
Total 23 3 1
Fig. 1. (A) Ki67 staining was detected in 80% of tumor cell nuclei under a light microscope (original magnification ×400). (B) Ki67 staining was
detected in 10% of tumor cell nuclei under a light microscope (original magnification ×400).
A BStatistical analysis
The survival rate and the correlation between Ki67 expression
and each factor were assessed using the Kaplan-Meier method
and the log-rank test using the SPSS software (SPSS Inc., Chicago,
IL, USA). A P-value <0.05 was considered to be statistically sig-
nificant.
RESULTS
The most common presenting symptoms are nasal obstruction
followed by epistaxis (Table 2). The 5-yr survival rate based on
the Kaplan-Meier method was 35.3% for MMM of the sinonasal
tract (Fig. 2). In the follow-up period, 17 patients (62.9%) showed
recurrence; 10 local recurrences (37.0%), four regional recurrences
(14.8%), and three distant metastases (11.1%). In the cases of
distant metastasis, cancerous cells invaded the brain, lung, and
lower abdomen. The mean interval between surgical excision and
recurrence was 6.9 months. 
No significant differences in the 5-yr survival rate were observed
with regard to age, sex, stage or the presence of melanin (Table 3).
However, histological cell type had an impact on prognosis. Patients
with spindle or mixed cell types showed significantly higher 5-yr
survival rates than those with other cell types (Table 4). Patients
with scores of <35% for Ki67 positive staining in tumor cells also
had significantly higher 5-yr survival rates than those with scores
≥35% (Fig. 3).
DISCUSSION
Cutaneous melanoma is more common in Caucasians than in Asi-
ans, whereas mucosal melanoma is relatively common in Asians
(11). More than one-third of patients are diagnosed as having ame-
lanotic MMM in Western, in which diagnosis tends to be delayed
because of atypical symptoms and signs (12). From our series of
patients, amelanotic MMM was found in twelve patients (44.4%)
which is slightly higher when compared to the previous reports
(13). Furthermore, a precursor lesion, such as the nevus in cuta-
neous malignant melanoma, has not yet been identified (12).
The symptoms at diagnosis depend on the site of the primary
lesion. Since the most common sites are the turbinate and septum,
patients frequently present with unilateral nasal obstruction and
epistaxis (14). However, in advanced stages, pain and facial defor-
mity may also be present (3). Our results are consistent with pre-
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N 5-yr survival rate P-value
Table 3. Survival rate according to age, sex, stage, and the presence
of melanin
Initial symptoms N* Anatomical site N*
Table 2. Initial symptoms and anatomic site at initial presentation
*Numbers are not mutually exclusive.
Nasal obstruction 12 Middle turbinate 14
Epistaxis 10 Inferior turbinate 13
Watery rhinorrhea 2 Septum 10
Pain 2 Maxillary sinus 8
Cheek swelling 2 Ethmoid sinus 8
Posterior nasal drip 1 Nasal floor 6
Headache 1 Skull base 3
Exophthalmos 1 Orbit 2
Blindness 1 Others 2
Age 0.801
≤65 yr 13 20.8%
>65 yr 14 44.0%
Sex 0.348
Male 15 29.2%
Female 12 40.9%
Stage 0.455
I 23 37.7%
II & III 4 0.0%
Melanin 0.140
Present 9 68.6%
Absent 12 12.5%
Cell type N=21 5-yr survival rate P-value
Table 4. Survival rate according to cell type
Rhabdoid 2 0%
Mixed 7 55.6% *0.044
Epitheloid 4 0%
Spindle 6 75% *0.021
Undifferentiated 2 0%
*When compared to patients with epitheloid cells, patients with mixed and
spindle cells showed significantly higher 5-yr survival rates.
Fig. 2. The 5-yr survival rate for patients with mucosal malignant mel-
anoma of the sinonasal tract is 35.3%.
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vious reports regarding the age, sex, and symptoms presented at
the initial diagnosis. 
It has been reported that 81% of primary MMMs arise from
the nasal cavity and 19% from the sinuses (15). We found that
75% of primary MMMs originated from the nasal cavity and
25% from the sinuses. The present study demonstrates that the
turbinate and septum are the most common anatomic sites for
mucosal melanoma. 
Stern’s classification is universally used to stage tumors (10).
However, many studies have reported on stage I tumors at the
initial diagnosis and have found that stage is not associated with
survival. Likewise, 85.2% of the tumors in our patients were at
stage I, and there was no significant difference in survival accord-
ing to stage. Recently, other staging systems have been suggest-
ed for primary MMM (2, 16). However, these staging systems are
also irrelevant with survival in our data. These outcomes indicate
that a modified staging system is needed.
Local recurrence is a common problem in MMM. Previous stud-
ies have shown that the local recurrence rate is greater than 50%
(6), and this study showed a relatively high rate of local recur-
rence (37.0%). This high rate of local recurrence may result from
the non-apparent diffusion of tumor cells via the submucosal lym-
phatic route or the presence of multifocal lesions (6). Unlike squa-
mous cell carcinoma, MMM of the sinonasal tract metastasizes
to distant regions, such as the lung and brain, more frequently
than it undergoes cervical nodal metastasis (17). However, in our
series the regional metastasis rate is similar to the distant metas-
tasis rate. 
Previous studies have reported that the 5-yr survival rate for
malignant mucosal melanoma of the head and neck ranges from
0% to 44% (1, 3, 7, 12), which is consistent with our value of
35.3%. The 5-yr survival rate was not correlated with age, sex,
stage, or the presence of melanin.
We also analyzed the survival rate with respect to histologi-
cal cell type and found that patients with spindle or mixed cell
types had a better prognosis. However, the number of patients
available for the histological study was small and future large-scale
studies are required to confirm our results.
Intense immunohistochemical staining for Ki67 is correlated
with poor prognosis in various malignancies, including cutaneous
malignant melanoma (8, 9, 18, 19). One small series reported that
scores of ≤40% for Ki67 and ≤80% for PCNA were correlat-
ed with good prognosis in anorectal malignant melanoma (17).
Another study reported that scores of ≤20% for Ki67 and ≤35%
for PCNA were correlated with good prognosis in cutaneous malig-
nant melanoma (18). However, there is no information available
regarding the association between survival and Ki67 staining in
MMM. This study showed that Ki67 staining in <35% of tumor
cells is statistically correlated with a good prognosis, which indi-
cates that Ki67 antigen may be useful in a prognostic factor for
MMM.
CONCLUSIONS
MMM of the sinonasal tract shows frequent local recurrence and
poor prognosis. Even though the number of participants in this
study is small, we demonstrate that patients with spindle cells
or mixed cell types generally have better prognoses than patients
with other cell types and that Ki67 immunohistochemical stain-
ing may be a useful marker to predict the prognosis for MMM
of the sinonasal tract.
Fig. 3. (A) We determined cut-off value at 35% by ROC curve. (B) Patients with scores of <35% for Ki67 staining have a distinct survival advan-
tage over those patients with scores of ≥35%.
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